Figure 4 .

The S-II subtype patients are more likely to benefit from immunotherapies

A. The clinical characteristics of the patients from the ICI cohort. B. and C. In the ICI cohort, the S-II patients had the best PFS time when receiving first-line immunotherapy (B) but showed no statistically obvious difference compared with S-I/S-III patients when receiving second-line immunotherapy (C). D. In all S-II patients, patients after immunotherapy had better OS than those without immunotherapy. S-II patients in the ICI cohort and S-II patients who did not receive immunotherapy in the discovery and validation cohorts were used for analysis. P values were determined by log-rank test (*, P < 0.05; ****, P < 0.0001; n.s., not significant).